Twist Bioscience Co. (NASDAQ:TWST) Receives $54.40 Average Price Target from Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $54.40.

Several brokerages have recently issued reports on TWST. Barclays set a $58.00 price target on Twist Bioscience and gave the company an "overweight" rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Robert W. Baird lifted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 5,200 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $256,620.00. Following the completion of the sale, the chief executive officer now owns 667,318 shares of the company's stock, valued at approximately $32,932,143.30. This represents a 0.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert Chess sold 2,940 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the sale, the director now directly owns 18,173 shares in the company, valued at $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,799 shares of company stock worth $1,593,944. Corporate insiders own 3.01% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA boosted its stake in Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock valued at $1,324,000 after purchasing an additional 20,035 shares during the period. Barclays PLC lifted its holdings in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after buying an additional 104,420 shares in the last quarter. FMR LLC boosted its position in shares of Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company's stock valued at $9,875,000 after acquiring an additional 12,327 shares during the period. Avanza Fonder AB acquired a new position in shares of Twist Bioscience in the fourth quarter valued at about $1,059,000. Finally, BNP Paribas Financial Markets increased its position in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock worth $1,718,000 after acquiring an additional 21,357 shares during the period.

Twist Bioscience Price Performance

NASDAQ TWST traded down $0.30 on Monday, hitting $41.58. 643,757 shares of the company were exchanged, compared to its average volume of 924,398. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.48 billion, a P/E ratio of -12.30 and a beta of 2.15. Twist Bioscience has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a 50 day moving average of $45.38 and a two-hundred day moving average of $45.34.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter last year, the business posted ($0.75) earnings per share. Twist Bioscience's revenue for the quarter was up 24.1% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience will post -2.12 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.